Cargando…
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-c...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099725/ https://www.ncbi.nlm.nih.gov/pubmed/35566632 http://dx.doi.org/10.3390/jcm11092509 |
_version_ | 1784706677450211328 |
---|---|
author | Sancho-Saldaña, Agustín Gil Sánchez, Anna Quirant-Sánchez, Bibiana Nogueras, Lara Peralta, Silvia Solana, Maria José González-Mingot, Cristina Gallego, Yhovanni Quibus, Laura Ramo-Tello, Cristina Presas-Rodríguez, Silvia Martínez-Cáceres, Eva Torres, Pascual Hervás, José Vicente Valls, Joan Brieva, Luis |
author_facet | Sancho-Saldaña, Agustín Gil Sánchez, Anna Quirant-Sánchez, Bibiana Nogueras, Lara Peralta, Silvia Solana, Maria José González-Mingot, Cristina Gallego, Yhovanni Quibus, Laura Ramo-Tello, Cristina Presas-Rodríguez, Silvia Martínez-Cáceres, Eva Torres, Pascual Hervás, José Vicente Valls, Joan Brieva, Luis |
author_sort | Sancho-Saldaña, Agustín |
collection | PubMed |
description | Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-center prospective observational study based on data from the Esclerosis Múltiple y COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data and SARS-CoV-2 serology, and symptoms of COVID-19 in pwMS treated with any DTM were extracted. The relationship among demographics, MS status, DMT, and COVID-19 was evaluated. Results: A total of 259 pwMS were included. The administration of interferon was significantly associated with the presence of SARS-CoV-2 antibodies (26.4% vs. 10.7%, p = 0.006). Although patients taking interferon were significantly older (49.1 vs. 43.5, p = 0.003), the association of interferon with the presence of SARS-CoV-2 antibodies was still significant in the multivariate analysis (OR 2.99 (1.38; 6.36), p = 0.006). Conclusions: According to our data, pwMS present a higher risk of COVID-19 infection compared with results obtained from the general population. There is no evidence of a worse COVID-19 outcome in pwMS. DMTs did not significantly change the frequency of COVID-19, except for interferon; however, these findings must be interpreted with caution given the small sample of pwMS taking each DMT. |
format | Online Article Text |
id | pubmed-9099725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90997252022-05-14 Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies Sancho-Saldaña, Agustín Gil Sánchez, Anna Quirant-Sánchez, Bibiana Nogueras, Lara Peralta, Silvia Solana, Maria José González-Mingot, Cristina Gallego, Yhovanni Quibus, Laura Ramo-Tello, Cristina Presas-Rodríguez, Silvia Martínez-Cáceres, Eva Torres, Pascual Hervás, José Vicente Valls, Joan Brieva, Luis J Clin Med Article Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-center prospective observational study based on data from the Esclerosis Múltiple y COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data and SARS-CoV-2 serology, and symptoms of COVID-19 in pwMS treated with any DTM were extracted. The relationship among demographics, MS status, DMT, and COVID-19 was evaluated. Results: A total of 259 pwMS were included. The administration of interferon was significantly associated with the presence of SARS-CoV-2 antibodies (26.4% vs. 10.7%, p = 0.006). Although patients taking interferon were significantly older (49.1 vs. 43.5, p = 0.003), the association of interferon with the presence of SARS-CoV-2 antibodies was still significant in the multivariate analysis (OR 2.99 (1.38; 6.36), p = 0.006). Conclusions: According to our data, pwMS present a higher risk of COVID-19 infection compared with results obtained from the general population. There is no evidence of a worse COVID-19 outcome in pwMS. DMTs did not significantly change the frequency of COVID-19, except for interferon; however, these findings must be interpreted with caution given the small sample of pwMS taking each DMT. MDPI 2022-04-29 /pmc/articles/PMC9099725/ /pubmed/35566632 http://dx.doi.org/10.3390/jcm11092509 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sancho-Saldaña, Agustín Gil Sánchez, Anna Quirant-Sánchez, Bibiana Nogueras, Lara Peralta, Silvia Solana, Maria José González-Mingot, Cristina Gallego, Yhovanni Quibus, Laura Ramo-Tello, Cristina Presas-Rodríguez, Silvia Martínez-Cáceres, Eva Torres, Pascual Hervás, José Vicente Valls, Joan Brieva, Luis Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies |
title | Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies |
title_full | Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies |
title_fullStr | Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies |
title_full_unstemmed | Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies |
title_short | Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies |
title_sort | seroprevalence of sars-cov-2 in a cohort of patients with multiple sclerosis under disease-modifying therapies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099725/ https://www.ncbi.nlm.nih.gov/pubmed/35566632 http://dx.doi.org/10.3390/jcm11092509 |
work_keys_str_mv | AT sanchosaldanaagustin seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT gilsanchezanna seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT quirantsanchezbibiana seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT nogueraslara seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT peraltasilvia seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT solanamariajose seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT gonzalezmingotcristina seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT gallegoyhovanni seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT quibuslaura seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT ramotellocristina seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT presasrodriguezsilvia seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT martinezcacereseva seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT torrespascual seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT hervasjosevicente seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT vallsjoan seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies AT brievaluis seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies |